Formulation Development
Coya Therapeutics Announces $5-Million Strategic Investment by the Alzheimer’s Drug Discovery Foundation
Coya Therapeutics, Inc. recently announces the Alzheimer’s Drug Discovery Foundation (ADDF) has purchased 603,136 shares of the company’s common stock at a purchase price of…
GRI Bio Presents Positive Preclinical Data Demonstrating Lead Program Reduces the Important Inflammatory & Fibrotic Drivers in Idiopathic Pulmonary Fibrosis
GRI Bio, Inc. recently presented positive preclinical data demonstrating its lead program GRI-0621 reduces the important inflammatory and fibrotic drivers in Idiopathic Pulmonary Fibrosis (IPF).…
Tourmaline Bio Initiates Clinical Development of TOUR006 for Cardiovascular Diseases With First Patient Dosed in Phase 2 TRANQUILITY Trial
Tourmaline Bio, Inc. recently announced the first patient has been dosed in its Phase 2 TRANQUILITY trial, marking the initiation of its clinical development program…
Voyager Therapeutics Announces First Participants Dosed in Single Ascending Dose Trial of VY-TAU01 for the Treatment of Alzheimer’s Disease
Voyager Therapeutics, Inc. recently announced that the first participants were dosed in a Phase 1a single ascending dose (SAD) trial of VY-TAU01, an investigational anti-tau…
MoonLake Immunotherapeutics Starts Phase 3 VELA Program of the Nanobody Sonelokimab in Patients With Moderate-to-Severe Hidradenitis Suppurativa
MoonLake Immunotherapeutics recently announced the first patients have been screened at a US trial site in its global Phase 3 clinical program, VELA, evaluating sonelokimab,…
Ocean Biomedical Announces Patent Allowance for Malaria Antibodies That Have Potential Capability to Protect Against Infection & Treat Severe Disease
Ocean Biomedical recently announced that Scientific Co-founder Dr. Jonathan Kurtis, MD, PhD, has been granted a new patent for his malaria therapeutic antibody discoveries, targeted…
Avenue Therapeutics Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal & Bulbar Muscular Atrophy
Avenue Therapeutics, Inc. recently announced the completion of the last patient’s final visit in the company’s Phase 1b/2a clinical trial of AJ201 for the treatment…
Veranova & Phorum.AI Partner to Deliver Generative AI Chemistry Optimization to the Pharmaceutical & Biotech Industry
Veranova and Phorum.AI recently announced they are collaborating on next-generation optimization of pharmaceutical manufacturing processes using artificial intelligence (AI). Building on years of research and…
TFF Pharmaceuticals Provides Update on Tacrolimus Inhalation Powder Phase 2 Trial for the Prevention of Lung Transplant Rejection
TFF Pharmaceuticals, Inc. provided an update from the its ongoing Phase 2 trial of Tacrolimus Inhalation Powder (TFF TAC) for the prevention of lung transplant…
Medigene Presents Preclinical Data on Optimal Affinity TCRs Targeting the Neoantigen Mutant KRAS
Medigene AG recently presented the company’s proprietary T cell receptor (TCR) discovery process to obtain optimal affinity 3S (sensitive, specific and safe) TCRs at the…
PlaqueTec & the Babraham Institute Collaborate on Early Phase Target Discovery & Development
Campus Innovation Award (CIA)-funded project evaluated lead compounds predicted to bind a pro-inflammatory protein discovered by PlaqueTec….
Roquette Unlocks the Power of Flexibility With Launch of New Flex Softgel Capsule Shell System
Roquette recently announced the launch of its new LYCAGEL Flex hydroxypropyl pea starch premix for nutraceutical and pharmaceutical softgel capsules. Built on Roquette’s market-first LYCAGEL pea…
CellProthera Announces Positive Phase 1/2b Data for ProtheraCytes Cell Therapy in Acute Myocardial Infarction
CellProthera recently announced positive results from a Phase 1/2b study of its lead ProtheraCytes in patients following a severe heart attack, positioning the stem cell…
ElevateBio Announces New US Patents for Lead Life Edit CRISPR Systems & Adenine Deaminases Enabling Advanced Gene Editing Techniques
ElevateBio is building a robust portfolio of patents protecting its novel technologies while the Company scales as the world’s first integrated genetic medicine foundry….
PTC Therapeutics Announces FDA Acceptance & Priority Review of BLA
PTC Therapeutics, Inc. recently announced the FDA has accepted for filing the Biologics License Application (BLA) for Upstaza (eladocagene exuparvovec), a gene therapy for the…
Tavros Therapeutics Achieves Two Milestone Payments in its Collaboration With Vividion Therapeutics
Tavros Therapeutics, Inc. recently announced it has achieved two milestone payments in its collaboration with Vividion Therapeutics, Inc., a wholly owned and independently operated subsidiary…
CENTOGENE & Evotec Discover Promising New Molecule to Treat Gaucher Disease
Centogene N.V. recently announced the discovery of a new small molecule together with Evotec SE. The new molecule has the potential to treat patients with…
Silo Pharma to Participate in FDA Meeting Exploring Emerging Therapeutic Interest in Ketamine
Silo Pharma, Inc. recently announced its planned attendance at a hybrid public meeting on June 27, 2024, hosted by the US FDA in partnership with…
AbbVie & Gilgamesh Pharmaceuticals Announce Collaboration & Option-to-License Agreement to Develop Next-Generation Therapies for Psychiatric Disorders
Collaboration to leverage AbbVie’s psychiatry expertise and Gilgamesh’s innovative research platform to develop next-generation neuroplastogens for the treatment of psychiatric disorders….
AC Immune & Takeda Sign Exclusive Option & License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease
Takeda to receive exclusive option to license global rights to ACI-24.060, a potential first-in-class active immunotherapy designed to delay or slow Alzheimer’s disease progression….
